One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Cerebrovascular Accident Risk in Survivors of Head and Neck Cancer: JACC CardioOncology State-of-the-Art Review
doi : 10.1016/j.jaccao.2026.06.003
Volume 8, Issue 4, August 2026, Pages 339-356
Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer
doi : 10.1016/j.jaccao.2026.07.006
Volume 8, Issue 4, August 2026, Pages 357-363
A Simple Clinical Risk Score to Improve Prediction of Anthracycline-Induced Cardiotoxicity
doi : 10.1016/j.jaccao.2026.06.005
Volume 8, Issue 4, August 2026, Pages 364-375
The Quest for a Safer Use of Anthracyclines Continues: Risk Prediction of Clinical Cardiotoxicity
doi : 10.1016/j.jaccao.2026.07.002
Volume 8, Issue 4, August 2026, Pages 376-377
Hemoglobin Decline After Oral Anticoagulation Initiation and Subsequent Cancer Detection in Patients With Atrial Fibrillation
doi : 10.1016/j.jaccao.2026.07.005
Volume 8, Issue 4, August 2026, Pages 378-391
Hemoglobin Decline and Occult Cancer After OAC Initiation: “No Smoke Without Fire?
doi : 10.1016/j.jaccao.2026.07.004
Volume 8, Issue 4, August 2026, Pages 392-394
Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk: Insights From Proteomic and Metabolomic Mediators
doi : 10.1016/j.jaccao.2026.05.012
Volume 8, Issue 4, August 2026, Pages 395-411
The Cardiometabolic-to-Cancer Axis: Molecular Insights From Cardio-Kidney-Metabolic Syndrome Staging
doi : 10.1016/j.jaccao.2026.06.004
Volume 8, Issue 4, August 2026, Pages 412-414
Divergent Effects of GnRH Agonist and GnRH Antagonist Treatment on Platelet Activity and Transcriptome
doi : 10.1016/j.jaccao.2026.07.007
Volume 8, Issue 4, August 2026, Pages 415-427
Do Platelets Explain Why GnRH Antagonists Are Potentially Safer From a Cardiovascular Perspective?
doi : 10.1016/j.jaccao.2026.07.003
Volume 8, Issue 4, August 2026, Pages 428-430
Sacubitril/Valsartan in Anthracycline-Treated Patients: A Systematic Review and Meta-Analysis of Available Evidence
doi : 10.1016/j.jaccao.2026.04.001
Volume 8, Issue 4, August 2026, Pages 431-433
Sacubitril/Valsartan and Right Ventricular and Diastolic Function During Breast Cancer Therapy
doi : 10.1016/j.jaccao.2026.06.002
Volume 8, Issue 4, August 2026, Pages 434-436
A Clinically Applicable Conversion Formula Between NT-proBNP and BNP in Light-Chain Amyloidosis
doi : 10.1016/j.jaccao.2026.06.001
Volume 8, Issue 4, August 2026, Pages 437-439
Statin Use Attenuates Leuprolide-Associated Coronary Atherosclerosis Progression: A Secondary Analysis of the REVELUTION Trial
doi : 10.1016/j.jaccao.2026.07.001
Volume 8, Issue 4, August 2026, Pages 440-442
Polygenic Risk Scores for Cardiovascular Risk Prediction in Breast Cancer Survivors: Implications for Asian Populations
doi : 10.1016/j.jaccao.2026.02.005
Volume 8, Issue 4, August 2026, Pages 443-444
Reply: Polygenic Risk Scores for Cardiovascular Disease in Breast Cancer Survivors: Implications for Asian Populations
doi : 10.1016/j.jaccao.2026.05.010
Volume 8, Issue 4, August 2026, Page 445
Refining the Prognostic Interpretation of Myocardial PD-L1 Expression in ICI-Associated Myocarditis
doi : 10.1016/j.jaccao.2026.04.010
Volume 8, Issue 4, August 2026, Page 446
Reply: Refining the Prognostic Interpretation of Myocardial PD-L1 Expression in ICI-Associated Myocarditis
doi : 10.1016/j.jaccao.2026.05.011
Volume 8, Issue 4, August 2026, Page 447
When “Uptake” Is Organelle Biology: Derisking CRISPR Anthracycline Cardiotoxicity Screens
doi : 10.1016/j.jaccao.2026.03.009
Volume 8, Issue 4, August 2026, Page 448
